Testing a new PET scan tracer to stage newly diagnosed non-small cell lung cancer
Tests 68Ga-FAPI-46 PET imaging in adults newly diagnosed with non-small cell lung cancer.
Key facts
- Who runs it
- Academisch Ziekenhuis Maastricht
- Where
- Maastricht, NetherlandsSee the site
- Trial code
- Registry title
- Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer – a pilot study
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 10 people, planned
- Started
- 2 Feb 2026
- Expected to end
- 1 Feb 2027
- Type of study
- Interventional
- Record updated
- 3 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed non-small cell lung cancer (NSCLC) proven by biopsy. It compares a new PET scan tracer (68Ga-FAPI-46) with the standard scan.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Biopsy-proven non-small cell lung cancer that needs, or already had, an 18F-FDG PET/CT scan as part of diagnosis
- Earlier treatment
- No earlier lung cancer treatment and no earlier lung surgery
Main reasons for not taking part
- History of lung cancer (treatment) or lung surgery
- Other cancer in the 5 years before the NSCLC diagnosis (except carcinoma in situ, melanoma in situ)
- Chronic inflammatory disease such as rheumatoid arthritis or fibrotic lung conditions
- Severe kidney problems (eGFR ≤30 mL/min/1.73 m²)
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Biopsy proven NSCLC needing 18F-FDG PET/CT for diagnostic workup or biopsy proven NSCLC with 18F-FDG PET/CT already performed
- Age ≥ 18
- ECOG score 0-2
- Possibility to perform 68Ga-FAPI-46 PET with low dose CT within three weeks after 18F-FDG PET/CT
- Willing and able to undergo brain MRI if not already performed or scheduled in regular care
- Provision of signed and dated, written informed consent
Who cannot take part
- History of lung cancer (treatment) or lung surgery
- History of other malignancies 5 years prior to the current diagnosis of NSCLC (except carcinoma in situ, melanoma in situ)
- Chronic inflammatory disease such as rheumatoid arthritis or fibrotic pulmonary conditions
- Known allergy to MRI contrast agent (i.e gadolinium-based contrast agents) or CT contrast agent (iodinated contrast)
- Patients with severe renal impairment (eGFR≤30mL/min/1.73m²; the nuclear tracer is primarily excreted through the kidneys. If a patient has severe renal impairment, clearance is reduced, leading to prolonged circulation of the nuclear tracer in the body)
- Pregnant and lactating women
- Brain tumor (including meningioma)
- Contra-indication for MRI such as claustrophobia, pacemaker, clips, severe obesity
Where in Netherlands
- Maastricht University Medical CenterMaastricht, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
The aim of this pilot study is to determine essential input parameters for an adequate sample size calculation for a subsequent diagnostic study that compares the diagnostic accuracy of standard 18F-FDG and brain MRI versus 68Ga -FAPI as PET tracer in patients with newly diagnosed NSCLC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer – a pilot study
- Plain-language title
- Testing a new PET scan tracer to stage newly diagnosed non-small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 3 February 2026